{"id":"eque-cel-car-t-therapy","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Cytokine release syndrome"},{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"10-20%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CAR-T cells are genetically modified to express a chimeric antigen receptor that recognizes CD19, leading to the selective killing of CD19-positive B cells.","oneSentence":"CAR-T cell therapy targets CD19-positive B cells","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:59:41.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell lymphoma"},{"name":"Relapsed or refractory diffuse large B-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT07055724","phase":"PHASE2","title":"Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis","status":"NOT_YET_RECRUITING","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","startDate":"2025-07","conditions":"AL Amyloidosis","enrollment":17},{"nctId":"NCT06902844","phase":"NA","title":"Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-04-05","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Eque-cel CAR-T Therapy","genericName":"Eque-cel CAR-T Therapy","companyName":"Nanjing IASO Biotechnology Co., Ltd.","companyId":"nanjing-iaso-biotechnology-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"CAR-T cell therapy targets CD19-positive B cells Used for Relapsed or refractory B-cell lymphoma, Relapsed or refractory diffuse large B-cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}